Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma

Journal of Clinical Oncology

Volumn 33, Issue 28, 2015, Pages 3124-3129

  Holter, Spring ^a   Borgida, Ayelet ^a   Dodd, Anna ^b   Grant, Robert ^a   Semotiuk, Kara ^a   Hedley, David ^b   Dhani, Neesha ^b   Narod, Steven ^c   Akbari, Mohammad ^c   Moore, Malcolm ^b   Gallinger, Steven ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c WOMEN S COLLEGE HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; DNA; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN, HUMAN;

ADULT; AGED; CANCER FAMILY; CANCER THERAPY; COHORT ANALYSIS; CONFERENCE PAPER; CONFIDENCE INTERVAL; FAMILY HISTORY; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC RISK; GENETIC SCREENING; GENETIC VARIABILITY; GERMLINE MUTATION; HUMAN; JEW; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; PANCREAS ADENOCARCINOMA; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; DNA MUTATIONAL ANALYSIS; EPIDEMIOLOGY; ETHNOLOGY; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; HEREDITY; INCIDENCE; MULTIPLEX POLYMERASE CHAIN REACTION; ONTARIO; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PEDIGREE; PHENOTYPE; PROCEDURES; PROGNOSIS; RISK FACTOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BRCA1 PROTEIN; BRCA2 PROTEIN; CARCINOMA, PANCREATIC DUCTAL; DNA MUTATIONAL ANALYSIS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HEREDITY; HUMANS; INCIDENCE; JEWS; MALE; MIDDLE AGED; MULTIPLEX POLYMERASE CHAIN REACTION; ONTARIO; PANCREATIC NEOPLASMS; PEDIGREE; PHENOTYPE; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84941261769     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.59.7401     Document Type: Conference Paper

References (39)

1. Lal G, Liu G, Schmocker B, et al: Inherited predisposition to pancreatic adenocarcinoma: Role of family history and germ-line p16, BRCA1, and BRCA2 mutations. Cancer Res 60: 409-416, 2000
2. Jones S, Hruban RH, Kamiyama M, et al: Exomic sequencing identifies PALB2 as a pancreatic susceptibility gene. Science 324: 217, 2009
3. McWilliams R, Wieben E, Rabe K, et al: Prevalence of CDKN2A mutations in pancreatic cancer patients: Implication for genetic counseling. Eur J Human Genet 19: 472-478, 2011
4. Resta N, Pierannunzio D, Lenato GM, et al: Cancer risk associated with STK11/LKB1 germline mutations in Peutz-Jeghers syndrome patients: Results from an Italian multicenter study. Dig Liver Dis 45: 606-611, 2013
5. Roberts NJ, Jiao Y, Yu J, et al: ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov 2: 41-46, 2012
6. Win AK, Young JP, Lindor NM, et al: Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: A prospective cohort study. J Clin Oncol 30: 958-964, 2012
7. Tersmette AC, Petersen GM, Offerhaus GJ, et al: Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. Clin Cancer Res 7: 738-744, 2001
8. The Breast Cancer Linkage Consortium: Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 91: 1310-1316, 1999
9. Risch HA, McLaughlin JR, Cole DE, et al: Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: A kin-cohort study in Ontario, Canada. J Natl Cancer Inst 98: 1694-1706, 2006
10. Thompson D, Easton DF, the Breast Cancer Linkage Consortium: Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94: 1358-1365, 2002
11. Iqbal J, Ragone A, Lubinski J, et al: The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer 107: 2005-2009, 2012
12. Ferrone CR, Levine DA, Tang LH, et al: BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. J Clin Oncol 27: 433-438, 2008
13. Lucas AL, Shakya R, Lipsyc MD, et al: High prevalence of BRCA1 and BRCA2 germline mutations with loss of heterozygosity in a series of resected pancreatic adenocarcinoma and other neoplastic lesions. Clin Cancer Res 19: 3396-3403, 2013
14. Hahn SA, Greenhalf B, Ellis I, et al: BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst 95: 214-221, 2003
15. Murphy KM, Brune KA, Griffin C, et al: Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: Deleterious BRCA2 mutations in 17%. Cancer Res 62: 3789-3793, 2002
16. Couch FJ, Johnson MR, Rabe KG, et al: The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev 16: 342-346, 2007
17. Ozçelik H, Schmocker B, Di Nicola N, et al: Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients. Nat Genet 16: 17-18, 1997
18. Goggins M, Schutte M, Lu J, et al: Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 56: 5360-5364, 1996
19. Golan T, Kanji ZS, Epelbaum R, et al: Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer 111: 1132-1138, 2014
20. Lowery MA, Kelsen DP, Stadler ZK, et al: An emerging entity: Pancreatic adenocarcinoma associated with a known BRCA mutation-Clinical descriptors, treatment implications, and future directions. Oncologist 16: 1397-1402, 2011
21. National Comprehensive Cancer Network: NCCN Guidelines Version 2.2014: Guidelines for Detection, Prevention, and Risk Reduction-Genetic/Familial High-Risk Assessment: Breast and Ovarian. http://www.nccn.org/professionals/physician-gls/f-guidelines.asp
22. Borgida AE, Ashamalla S, Al-Sukhni W, et al: Management of pancreatic adenocarcinoma in Ontario, Canada: A population-based study using novel case ascertainment. Can J Surg 54: 54-60, 2011
23. Ewald IP, Ribeiro PL, Palmero EI, et al: Genomic rearrangements in BRCA1 and BRCA2: A literature review. Genet Mol Biol 32: 437-446, 2009
24. Kurian AW, Hare EE, Mills MA, et al: Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. J Clin Oncol 32: 2001-2009, 2014
25. LaDuca H, Stuenkel AJ, Dolinsky JS, et al: Utilization of multigene panels in hereditary cancer predisposition testing: Analysis of more than 2,000 patients. Genet Med 16: 830-837, 2014
26. Domchek SM, Bradbury A, Garber JE, et al: Multiplex genetic testing for cancer susceptibility: Out on a high wire without a net? J Clin Oncol 31: 1267-1270, 2013
27. Tischkowitz MD, Sabbaghian N, Hamel N, et al: Analysis of the gene coding for the BRCA2-interacting protein PALB2 in familial and sporadic pancreatic cancer. Gastroenterology 137: 1183-1186, 2009
28. Harinck F, Kluijt I, van Mil SE, et al: Routine testing for PALB2 mutations in familial pancreatic cancer families and breast cancer families with pancreatic cancer is not indicated. Eur J Hum Genet 20: 577-579, 2012
29. Gargiulo S, Torrini M, Ollila S, et al: Germline MLH1 and MSH2 mutations in Italian pancreatic cancer patients with suspected Lynch syndrome. Fam Cancer 8: 547-553, 2009
30. Laitman Y, Herskovitz L, Golan T, et al: The founder Ashkenazi Jewish mutations in the MSH2 and MSH6 genes in Israeli patients with gastric and pancreatic cancer. Fam Cancer 11: 243-247, 2012
31. Farmer H, McCabe N, Lord CJ, et al: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434: 917-921, 2005
32. Tutt AN, Lord CJ, McCabe N, et al: Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. Cold Spring Harb Symp Quant Biol 70: 139-148, 2005
33. Sonnenblick A, Kadouri L, Appelbaum L, et al: Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy. Cancer Biol Ther 12: 165-168, 2011
34. Pennington KP, Walsh T, Harrell MI, et al: Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res 20: 764-775, 2014
35. Ashworth A: A synthetic lethal therapeutic approach: Poly(ADP)-ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 26: 3785-3790, 2008
36. National Institutes of Health: Olaparib in BRCA mutated pancreatic cancer who disease has not progressed on first line platinum-based chemotherapy (POLO). http://clinicaltrials.gov/show/NCT02184195
37. Levy-Lahad E, Catane R, Eisenberg S, et al: Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: Frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. Am J Hum Genet 60: 1059-1067, 1997
38. Al-Sukhni W, Borgida A, Rothenmund H, et al: Screening for pancreatic cancer in a high-risk cohort: An eight-year experience. J Gastrointest Surg 16: 771-783, 2012
39. Canto MI, Harinck F, Hruban RH, et al: International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut 62: 339-347, 2013